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PREFACE 
Transcriptional regulation is a fundamental process for the control of cell differentiation, 
morphogenesis and for the development, versatility and adaptability of any organism. In 
eukaryotes, a superfamily of DNA sequence-specific transcriptional factors termed nuclear 
receptors (NRs) regulate a diverse array of genes in responses to small ligands such as natural 
hormones and bioreactive metabolites (retinoids, vitamin D, cholesterol metabolites, bile 
acids, etc). NRs are important for many aspects of human biology. They mediate the 
transcriptional response to many endocrine signals involved in regulation of the reproductive 
process, development and oxidative metabolism, as well as lipid and energy metabolism and 
glucose homeostasis. NRs also play significant roles in human diseases/disorders ranging 
from breast and prostate cancer to diabetes and obesity. The basic mechanism for regulation 
of gene transcription by the NR relies on the essential participation and the dynamic and 
combinatorial interaction of a complex and growing network of coregulator proteins 
(coactivators and corepressors). Over the last few years, the pivotal roles of coregulator 
proteins in the turning-on and -off, and especially in the fine-tuning of transcriptional 
activation by NRs in response to different extracellular signals have become more evident. 
Abundant evidence has demonstrated that not only the NRs but also their coregulator proteins 
are subjected to regulation through posttranslational modifications such as phosphorylation, 
sumoylation, ubiquitination, acetylation and methylation, as well as intracellular translocation 
and proteasomal degradation. It is believed that regulation of coactivator and corepressor 
proteins is a critical mechanism for regulation of gene transcription by NRs in response to 
multiple signal transduction pathways. Thus, characterization of the molecular mechanisms 
that regulate coregulator protein functions is essential for the understanding of the biological 
roles of NRs and their related disorders. 
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INTRODUCTION 
1. Nuclear receptors 
1.1. Functional and structural domains 
Nuclear receptors (NRs) comprise a superfamily of ligand-inducible transcriptional factors. 
Members of the NR superfamily share common structural and functional domains designated 
as A to F (1) (Figure 1A). The N-terminal A/B region is sequence- and length-variable among 
the different receptor members, and contains the autonomous activation function AF-1. The C 
region represents the central highly conserved DNA binding domain (DBD) that consists of 
two zinc finger-like motifs. This domain is responsible for binding to specific target DNA 
elements that are known as the hormone response elements (HREs). The variable hinge 
domain (D) links the DBD to another conserved multifunctional C-terminal region (E) named 
the ligand-binding domain (LBD). The LBD encompasses the ligand-binding pocket, the 
second activation function (AF-2), a dimerization domain and a sequence responsible for 
nuclear localization. The LBDs of most NRs are formed by 12 conserved -helices numbered 
from H1 to H12, where the AF-2 domain is located in the H12. These helices are folded into a 
three-layered antiparallel helical sandwich forming a cavity which acts as the ligand-binding 
pocket (reviewed in (2)). While AF-1 is found only in certain members of the NR 
superfamily, in particularly the steroid receptors that contain a long N-terminus, and 
contributes to the constitutive ligand-independent activation by the receptors, the AF-2 is 
highly structurally conserved and plays critical roles in the ligand-dependent activation 
pathway (reviewed in  (3)). The C-terminal domain (F) is variable and found only in some 
NRs. The function of this domain is still unknown. 
 
1.2. Subfamilies and activation mechanisms 
Nuclear receptors have been subdivided into at least six subfamilies based on evolutionary 
analysis of their well-conserved domains, the DBD (C) and the LBD (E) (4). One large family 
is composed of thyroid hormone receptor (TRs), retinoid acid receptors (RARs), vitamin D 
receptors (VDRs), peroxisome proliferator-activated receptors (PPARs) and different orphan 
receptors such as RAR-related orphan receptor (RORs). The receptor for retinoid X (RXRs) 
together with certain orphan receptors including hepatocyte nuclear factor 4 (HNF4) comprise 
the second subfamily. The receptors for steroid hormones including estrogen receptor (ERs), 
androgen receptor (AR), glucocorticoid receptor (GR), progesterone receptor (PR) and 
mineralcorticoid receptor (MR), and the highly related orphan receptors estrogen-related 
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receptors (ERRs) form the third subfamily. The fourth, fifth and sixth subfamilies contain 
orphan receptors for which no ligand has yet been discovered. These subfamilies include 
NGF-induced factor B (NGFI-B), steroidogenic factor 1 (SF-1) and germ cell nuclear factor 
(GCNF) respectively. Following this classification, a unified nomenclature system for the NR 
superfamily has been developed to ease understanding of newly acquired knowledge to 
researchers outside and within the field (5). Selected mammalian NRs with details about 
receptor isoforms/subtypes and their nomenclature designated by the unified nomenclature 
system, cognate ligands and mode of DNA binding are listed in Table 1. 
 
 
 
 
A/B C D E F
N C
AF-2AF-1
DNA-binding Ligand binding
Dimerization
NLS
DBD HINGE LBD
N C
AF-2
DBD HINGE LBDFtzF1
1 462
FP
78 172 187 245
pAF
S203
NR
SF-1
A
B
 
 
Figure 1. The functional and structural domains of a nuclear receptor. A. The common structure of a 
nuclear receptor: the N-terminal region (A/B) harboring a ligand-independent activation function (AF-1), the 
DNA binding domain (DBD, C region), the hinge or linker region (D), the ligand-binding domain (LBD, region 
E/F) containing the activation function 2 (AF-2), and the F region. Functions of the DBD and LBD are indicated 
below the bars. B. SF-1 contains all the main functional domains of a NR, including the DBD, hinge and LBD. 
SF-1 does not have a classical AF-1, but the FP region encompassing the fushi tarazu factor 1 (Ftz-F1) box and a 
proline (P)-rich region, and the proximal activation domain (pAF). NLS: nuclear localization sequence. 
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Table 1. Selected mammalian nuclear receptors. The subtypes and their designated nomenclature, cognate 
ligands and mode of binding to target gene promoter of each NR are included (1,5,6). 
 
Receptor name Abbreviation 
and subtype 
Nomenclature Ligand DNA-
binding 
 
Thyroid hormone receptor 
 
Retinoic acid receptor 
 
Peroxisome proliferator 
activated receptor 
 
 
 
 
Reverse ErbA 
 
RAR-related orphan receptor 
 
 
Liver X receptor 
 
Farnesoid X receptor 
 
Vitamin D receptor 
 
Pregnane X receptor 
 
Constitutive androstane 
receptor 
Hepatocyte nuclear factor 4 
 
Retinoid X receptor 
 
Chicken ovalbumin upstream 
promoter transcription 
factor 
Estrogen receptor 
 
ER-related receptor 
 
Glucocorticoid receptor 
 
Mineralocorticoid receptor 
 
Progesterone receptor 
 
Androgen receptor 
 
NGF-induced factor B 
 
Steroidogenic factor 1 
 
Germ cell nuclear factor 
 
Dosage sensitive sex reversal 
 
TR,  
 
RAR, ,  
 
PPAR, ,  
 
 
 
 
 
RevErb,  
 
ROR, ,  
 
 
LXR,  
 
FXR,  
 
VDR 
 
PXR 
 
CAR 
 
HNF4,  
 
RXR, ,  
 
COUP-TFI, II 
 
 
ER,  
 
ERR, ,  
 
GR 
 
MR 
 
PR 
 
AR 
 
NGFI-B 
 
SF-1 
 
GCNF 
 
DAX-1 
 
NR1A1, 2 
 
NR1B1, 2, 3 
 
NR1C1, 2, 3 
 
 
 
 
 
NR1D1, 2 
 
NR1F1, 2, 3 
 
 
NR1H3, 2 
 
NR1H4, 5 
 
NR1I1 
 
NR1I2 
 
NR1I3 
 
NR2A1, 2 
 
NR2B1,2,3 
 
NR2F1, 2 
 
 
NR3A1, 2 
 
NR3B1, 2, 3 
 
NR3C1 
 
NR3C2 
 
NR3C3 
 
NR3C4 
 
NR4A1 
 
NR5A1 
 
NR6A1 
 
NR0B1 
 
Thyroid hormone (T3) 
 
Retinoic acid 
 
Benzotriene B4; Wy 14.643 
Eicosanoids; 
thiazolidinediones (TZDS); 
15-deoxy-12,41-prostaglandin 
J2; polyunsaturated fatty acids 
 
Unknown 
 
Cholesterol, cholesterol 
sulphate, retinoic acid 
 
Oxysterols 
 
Bile acids 
 
1-25(OH)2 vitamin D3 
 
Xenobiotics, pregnanes; C21 
steroids 
Xenobiotics, phenobarbital 
 
Fatty acyl CoA thioesters  
 
9-Cis-retinoic acid 
 
Unknown 
 
 
Estradiol 
 
Unknown, diethylstilbestrol 
4-OH tamoxifen 
Glucocorticoids 
 
Aldosterone, spirolactone 
 
Progestins 
 
Androgens 
 
Unknown 
 
Unknown 
 
Unknown 
 
Unknown 
 
H 
 
H 
 
H 
 
 
 
 
 
M, D 
 
H 
 
 
H 
 
H 
 
H 
 
H 
 
H 
 
D 
 
D 
 
D, H 
 
 
D 
 
M, D 
 
D 
 
D 
 
D 
 
D 
 
M, D, H 
 
M 
 
D 
 
 
M: Monomer, D: Dimer, H: Heterodimer 
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NRs regulate transcription of target genes by binding to specific DNA sequences known 
as hormone response elements (HREs) located in regulatory regions (promoters or enhancers) 
of the gene. NRs are initially activated through different mechanisms depending on their 
subclasses. The subfamily III steroid receptors, with the exception of ERs, recognise a HRE 
which is characterized by a palindrome/inverted repeat of a core hexanucleotide consensus 
sequence (AGAACA) spaced by three nucleotides. ERs bind to the consensus AGGTCA 
motifs with the same configuration. In the absence of hormones, steroid receptors exist as 
inactive protein complexes bound to heat shock proteins (Hsps), which help to maintain the 
receptors in a functionally folded state and at the same time to keep the receptors off from the 
DNA. Steroid hormones can enter their target cells by simple or facilitated diffusion through 
cell membranes. Upon binding to hormones/ligands, steroid receptors undergo conformational 
changes, dissociate from the Hsps, dimerize, bind to target HREs and subsequently activate 
transcription of the target genes (Figure 2A). Many receptors for non-steroidal hormones such 
as TRs, RARs, PPARs, and VDRs (subfamily I) appear to bind tightly to HREs constitutively, 
predominantly as a heterodimer with RXR, and confer an active transcriptional repression on 
their target genes. Therefore, activation of these receptors occurs primarily as steps 
subsequent to DNA-binding and ligand-binding which also lead to changes in their 
conformation (Fig 2B). The configuration of the non-steroidal receptor HREs may be 
palindromes, direct repeats or inverted palindromes of the core hexanucleotide AGGTCA 
with variable nucleotide spacing in between (reviewed in (6)). Many of the orphan receptors 
may still have unidentified ligands, while others may be activated constitutively or by other 
means than ligands. Orphan NRs are capable of binding to direct repeat HREs as heterodimers 
with RXR or homodimers, as well as recognising extended half sites HREs (AGG/TTCA) as 
monomers (reviewed in (7)). Despite the difference in their modes of initial activation, all 
NRs require association of transcriptional coregulator proteins for subsequent control of 
transcription activation of their target genes (see section 2). 
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Figure 2. Mechanisms for activation of steroid and non-steroidal receptors (edited from (8)). A, Steroid 
receptors (R) associate with chaperon heat shock proteins (Hsp) and are in inactive state in the absence ligands. 
Upon ligand binding, the receptors change their conformation, dissociate from the chaperon complex, dimerize 
and bind to their hormone response element (HRE) on target genes. Transcription of the target gene is 
subsequently activated. B, Certain non-steroid receptors (R) such as TRs, PPARs, and RARs are intrinsically 
bound to their HREs as homodimer or heterodimer with RXRs in the absence of ligands, and repress 
transcription of target gene. Ligand binding changes the receptor conformation, releases its repressive function, 
and activates formation of transcription complex to initiate transcription. 
 
1.3. Steroidogenic factor-1 
1.3.1. Functional and structural domains 
The orphan nuclear receptor Steroidogenic factor 1 (SF-1, also designated as Ad4BP/NR5A1) 
plays central roles in endocrine development and function at multiple levels of the 
hypothalamic-pituitary-steroidogenic axis (reviewed in (9)). The protein binds to a shared 
AGGTCA (Ad4) motif in the promoter region of genes encoding cytochrome P450 steroid 
hydroxylases of steroidogenesis, and is a key mediator for the tissue-specific expression of 
these genes (10,11). SF-1 was first recognised as a member of the NR superfamily through its 
high homology to the Drosophila nuclear receptor fushi tarazu factor 1 (12,13). Like other NR 
family members, SF-1 contains all the common functional and structural domains for a NR, 
i.e a characteristic zinc finger DBD, an intervening hinge region and a LBD which harbors an 
R
R
HRE
+
HspHsp
Target gene
A
HRE Target gene
R
HRE Target gene
B
R
R
S
H
S
S
R
S
R
H
HspHsp
H
R
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AF-2. SF-1 does not possess a classical AF-1, but has two other activating domains 
downstream to the DBD named the proximal activation function (pAF) harboring the serine 
residue at 203 (also called AF-1), and the FP region, which both cooperate with the AF-2 and 
are required for maximal activity of SF-1 (reviewed in (14)) (Fig 1B). The AF-2 of SF-1 
harbors a LLIEML conserved sequence which is necessary for transactivation of SF-1 target 
genes (15-17). This domain of SF-1 has been implicated in the transduction of the cAMP 
signal to transcriptional regulation of SF-1 target genes (18), and in interaction with several 
coactivator proteins (reviewed in (9,14)). SF-1 binds to its response DNA element as a 
monomer (14). 
 
1.3.2. Expression profile and biological roles 
SF-1 is specifically expressed in steroidogenic tissues including the adrenal cortex, ovarian 
theca and granulosa cells, as well as testicular Leydig cells (12,13). Studies on the expression 
profile of SF-1 during mouse embryonic development have revealed that SF-1 is expressed in 
the steroidogenic tissues from the earliest stages of organogenesis (19). In the later stages of 
embryonic development, SF-1 is expressed persistently in testes but diminish in ovaries 
(19,20). SF-1 is also expressed in the developing pituitary gland and in the precursor to the 
endocrine hypothalamus (diencephalons) (19). 
The essential roles of SF-1 in endocrine development and function have been clearly 
demonstrated by the development of targeted gene disruption in embryonic stem cells to 
create mice that are globally or tissue-specifically lacking SF-1. SF-1-knockout mice did not 
develop gonads or adrenal glands, died shortly after birth due to adrenal insufficiency, and 
exhibited a male-to-female sex reversal of their internal and external genitalia (21,22). The 
expression of several markers of pituitary gonadotrope cells including luteinizing hormone 
(LH) , follicle-stimulating hormone (FSH) , the -subunit of glycoprotein hormones and the 
receptor for gonadotropin releasing hormone, was also impaired in SF-1 knockout mice 
(23,24). Furthermore, knockout mice showed agenesis of the ventromedial hypothalamic 
nucleus which is linked to feeding and appetite regulation and female reproductive behavior 
(24-26), and showed defects in spleen development (27). Pituitary-specific ablation of SF-1 in 
mice has confirmed the pituitary origin of the absence of gonadotropin markers and delineated 
further that it is the absence of the gonadotropins that causes gonadal defects (26). 
In humans, function-disrupting mutations and polymorphisms of SF-1 protein have been 
found to be associated with certain defects and disorders of adrenocortical development 
and/or sexual differentiation.  One group has found a heterozygous G35E mutation that 
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caused XY reversal and adrenal failure in the patient (28). The mutation occurred at the 
proximal box of the first zinc finger that abolishes DNA binding ability of SF-1. Another 
group has identified a R255L heterozygous mutation in a 46 XX karyotype patient with 
normal ovary but with adrenal insufficiency (29). A homozygous R92Q mutation that leads to 
partial loss in the DNA-binding ability of SF-1 was also isolated in an infant patient with 
adrenal failure and complete 46XY sex reversal (30). Furthermore, in XY sex-reversal 
patients with gonadal agenesis, but with normal adrenal function, two types of SF-1 mutations 
were isolated, either a 8bp microdeletion that leads to early termination upstream of the AF-2 
domain or a C16X heterozygous mutation causing premature termination and abolishment of 
SF-1 activity (31,32). Gly146Ala polymorphism in the SF-1 sequence has also been identified 
and implicated as a susceptible factor for development of severe micropenis (33), 
development of type 2 diabetes and impaired insulin action in Chinese(34). 
 
1.3.3. Transcriptional regulation of target genes 
Accordant to its important roles in endocrine organogenesis and function, SF-1 regulates the 
expression of many genes involved in the endocrine processes along the hypothalamic-
pituitary-gonadal axis, as summarized in Table 2 (reviewed in (9,14)). Moreover, many of the 
SF-1 target genes encode major enzymes of the adrenal steroid biosynthesis, such as the 
cytochrome P450 cholesterol side-chain cleavage enzyme, 17-hydroxylase (CYP17), 3-
hydroxysteroid dehydrogenase, 21-hydroxylase (CYP21), and the steroidogenic acute 
regulatory protein (StAR). In most of the cases, SF-1 activates the basal expression of its 
target gene, and the transcriptional activation is induced constitutively in the absence of any 
exogenous ligands. It is still unclear whether the transcriptional activity of SF-1 is regulated 
by a physiological ligand in these cases. Although SF-1 was reported to be activated by 
oxysterols in certain cellular contexts (35), these molecules seem not to be its bona fide ligand 
(36). Recently, two independent groups have revealed the crystal structure of SF-1 and 
demonstrated that the second messenger phosphatidyl inositol (phospholipid) binds to SF-1 in 
its ligand binding pocket in the LBD, and that the ligand binding is required for maximal 
activity of SF-1 (37,38). However, the contribution of a ligand in regulation of SF-1 target 
genes remains to be elucidated. 
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Table 2. SF-1 target genes. SF-1 activates the basal activity of most of the genes except the gene encoding LH 
receptor in gonads/leydig cells whose basal transcription is inhibited. Transcriptional induction or inhibition of 
the genes by activation of the cAMP/PKA pathway is also indicated (9,14). 
 
Site of action Target gene Basal activity/ 
Induction 
Adrenal cortex 
 
 
 
 
 
 
 
 
 
Gonads 
Leydig cells 
 
 
 
 
 
 
Sertoli cells 
 
 
 
 
 
Theca and 
granulosa cells 
 
 
Pituitary 
Gonadotropes 
 
 
 
 
Ventromedial 
hypothalamic 
nucleus 
Gonadotropin-releasing hormone receptor 
Cytochrome P450 steroid hydroxylases 
 
3ß-hydroxysteroid dehydrogenase 
Steroidogenic acute regulatory protein (StAR) 
Corticotropin receptor 
Scavenger receptor-B1 
Hydromethylglutaryl-CoA reductase 
DAX-1 
Aldose reductase-like protein 
 
Cytochrome P450 steroid hydroxylases 
StAR 
LH receptor 
Insulin-like polypeptide 3 
Prolactin receptor 
Mullerian inhibiting substance (MIS) receptor 
 
MIS 
Inhibin 
FSH receptor 
Sex-determining region Y (SRY) 
SOX9 (SRY box) 
 
Cytochrome P450 steroid hydroxylases 
StAR 
Inhibin 
Oxytocin 
 
-subunit of glycoprotein hormones 
Luteinizing hormone (LH)  
Follicle-stimulating hormone (FSH)  
Gonadotropin-releasing hormone receptor 
 
N-methyl-D-aspartate receptor 
Basal 
basal + induction by cAMP 
(except for CYP11B2) 
basal 
basal + induction by cAMP 
basal + induction by cAMP 
basal + induction by cAMP 
basal 
basal 
basal 
 
basal + induction by cAMP 
basal + induction by cAMP 
basal inhibition 
basal 
basal 
basal 
 
basal 
basal + induction by cAMP 
basal + inhibition by PKA 
basal + inhibition by cAMP 
 
 
basal + induction by cAMP 
basal + induction by cAMP 
basal + induction by cAMP 
basal 
 
basal + induction by GnRH 
basal + induction by GnRH 
basal 
basal 
 
 
The absence of an exogenous ligand in activation of SF-1 has raised speculation on 
whether the receptor is regulated by alternative mechanisms involving signal transduction 
pathways. Considerable attention has been focused on the regulation of SF-1-mediated 
transcriptional activation in response to physiological cues, especially those involved in the 
endocrine homeostasis. cAMP is the intracellular secondary messenger molecule that 
transmits the signal of several extracellular tropic hormones, including the adrenocorticotropic 
hormone (ACTH) to cAMP-dependent protein kinase A (PKA) and the downstream signaling 
pathway (described in 3.2) (reviewed in (39,40)). Activation of the cAMP/PKA signaling 
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pathway has been shown to enhance SF-1-dependent gene transcription (41) and SF-1 seems 
to be required for cAMP-dependent expression of several genes encoding steroidogenic 
enzymes (42-46). While it has been demonstrated in vivo that SF-1 mRNA accumulation in 
the adrenals is not affected by an increased ACTH level (47), the effect of cAMP/PKA 
pathway activation on SF-1 expression appears to be far more complex and controversial in 
cell culture systems. The expression level of SF-1 can be unaffected or increased depending 
on cell types that are subjected to study (14). There is also evidence showing that activation of 
the PKA signaling pathway leads to an accumulation of SF-1 protein due to increased protein 
stability (48). One model that is recently developed from efforts to elucidate the molecular 
mechanism underlying regulation of SF-1 transcriptional activity by endocrine signals 
involves posttranslational modifications of the receptor and the implication of coregulators. 
Although it was demonstrated that SF-1 is phosphorylated in vitro by PKA (49), mutation of 
the serine residue in the consensus motif for PKA phosphorylation did not affect SF-1 
function in transfection assays (50). In addition, reports have suggested that the protein is not 
phosphorylated in vivo by PKA (48,51). However, Hammer and coworkers (51) have reported 
that the mitogen activated protein kinase (MAPK) phosphorylates SF-1 at a serine residue 
(Ser203) which is located in the AF-1 domain, and this phosphorylation leads to an enhanced 
transcriptional activation of SF-1 target genes and alterations in recruitment of selective 
nuclear cofactors. SF-1 is also subjected to sumoylation which represses its activity through 
stimulating recruitment of transcriptional repressors and/or relocation of SF-1 to nuclear 
speckles (52-54). Acetylation has also been observed as another mode of posttranslational 
modification of SF-1 that potentiates its transcriptional activity and mediates recruitment of 
coactivator proteins (55,56). Intriguingly, a recent study has reported that activation of the 
cAMP pathway increases SF-1 acetylation (56). Furthermore, Winnay and Hammer (57) have 
very recently demonstrated that the ACTH-dependent-signaling pathway modulates the 
temporal dynamic assembly of SF-1 and its associated coactivators on the promoter of a SF-1 
target gene encoding the melanocortin 2 receptor. The role of coregulator proteins in the 
transcriptional regulation by SF-1 and other NRs is further described in the following 
sections. 
 
2. Nuclear receptor coregulators 
DNA/HRE-binding or target gene recognition, which is either ligand-activated or constitutive, 
is generally a first essential step in a process of transcriptional regulation by a NR. However, 
subsequent recruitments of transcriptional cofactors/coregulators to the HRE-bound NR 
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determine the magnitude of transcriptional activity, either in an enhancing or a repressive 
manner, depending on the type of recruited transcriptional coregulators (classified as 
coactivators and corepressors). The concept for the existence of limiting transcriptional 
cofactors other than RNA polymerase and the basal transcription machinery, which are 
necessary for gene expression, came from the observation of transcriptional 
quenching/interference among different receptors (58,59). Later studies employing 
biochemical strategies provided the first evidence that ER associated directly with at least 
three mammalian proteins of 160, 140 and 80 kDa in a ligand- and LDB-dependent manner 
(60,61). The proteins were speculated to modulate the ligand-dependent transcriptional 
activation by ER. Following this finding, several coregulator proteins known as coactivators 
or corepressors have been cloned and characterized (reviewed in (6,62-65)). Coregulators are 
diverse both structurally and in the way they participate in the NR-dependent transcription 
process through their different enzymatic activities. Table 3 summarizes recently 
characterized properties and coregulatory roles of selected transcription coactivators and 
corepressors in the transcriptional regulation by NRs. 
 
2.1. Coregulator classes and regulatory roles in NR-dependent transcription 
Coactivators and corepressors do not bind to DNA, but associate with the DNA-bound NR in 
a sequential, combinatorial and temporally-regulated manner (64). Once recruited to HRE-
bound NRs, coactivator protein complexes stimulate the transcriptional activity by 
participating in chromatin remodeling and acting as bridging molecules for the recruitment 
and modification of RNA polymerase and the basal transcription machinery, including the 
template-activating factors and TATA-binding protein (TBP) (64). Five major classes of 
coactivators have been identified: i) coactivators of the p160/steroid receptor coactivator 
(SRC) family (described in section 2.3), ii) histone acetyltransferases (HATs)-possessing 
coactivators including CBP/p300 and pCAF/GCN5 which modulate chromatin structure and 
other transcriptional factors through acetylation (reviewed in (67)), iii) histone arginine 
methyltransferases (HMTs) such as CARM1 and PRMT1 which are able to methylate 
histones as well as other proteins (reviewed in (68)), iv) ATP-dependent nucleosome 
remodeling complexes such as SWI/SNF (reviewed in (69,70)), and v) the multisubunit 
mediator complex TRAP/DRIP/ARC which participate in transcription process by bridging 
the basal transcription machinery to the promoter-bound NR-coregulator complex (reviewed 
in (71,72)) (Table 3). Recruitment of these coactivator complexes to DNA-bound NRs and 
their coactivator actions in transcriptional activation is described further in section 2.3.2.
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Table 3. Nuclear receptor coactivators and corepressors. Properties and roles of selected coactivators and 
corepressors in transcriptional regulation by NRs are briefly specified (6,62-66). 
 
Coregulators Denomination Properties Role 
 
SRC-1 
SRC-2/GRIP1/TIF2 
 
 
SRC-3/p/CIP/ 
AIB1/ACTR/ 
RAC3/TRAM-1 
 
 
 
 
p300 
CBP 
 
p/CAF 
 
CARM1 
 
PRMT1 
 
BRG-1/hBrm 
(SWI/SNF) 
 
TRAP/DRIP/ARC 
 
 
 
PGC-1 
 
CoAA 
 
E6-AP 
UbcH7 
TBP-1 
 
 
PNRC/PNRC2 
 
GCN5 
 
RIP140 
 
 
LCoR 
 
SMRT/NCoR 
 
 
mSin3/HDACs 
 
 
SUN-CoR 
 
Steroid receptor coactivator-1 
Steroid receptor coactivator-2/ 
GR-interacting protein 1/ 
Transcription intermediary factor-2 
Steroid receptor coactivator-2/ 
p300/CBP/cointegrator-associated 
protein/Amplified in breast cancer 1/ 
Activator of the thyroid and retinoic 
acid receptor/Receptor-associated 
coactivator 3/TR activator molecule 1 
 
300-kD protein 
cAMP-response element binding 
(CREB)-binding protein 
p300/CBP-associated protein 
 
Coactivator-associated arginine 
methyltransferase 1 
Protein arginine methyltransferase 1 
 
Brahma (fly)-related gene 1/ 
Human homolog of BRG 
 
TR-associated protein/VDR-
interacting protein/Activator-
recruited cofactor 
 
PPAR coactivator-1 
 
Coactivator activator 
 
E6-associated protein 
Ubiquitin-conjugating enzyme 7 
TATA-binding protein-1 
 
 
Proline-rich nuclear receptor 
co-regulatory protein 
General control nonderepressed 5 
 
Receptor-interacting protein 140 
 
 
Ligand-dependent corepressor 
 
Silencing mediator of retinoic acid 
and thyroid hormone receptor/ 
Nuclear receptor corepressor 
Human homolog of yeast corepressor 
Sin3/Histone deacetylases 
 
Small ubiquitous nuclear corepressor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATP-dependent chromatin 
remodeling 
 
Reinitiation/maintenance 
complex-assembling 
 
 
Splicing-controlling, 
signal integrating 
Splicing-controlling 
 
Ubiquitin ligase 
Ubiquitin-conjugating 
Initiation complex-
assembling, ATPase 
 
 
 
HAT 
 
Signal-integrating 
 
 
Signal-integrating 
 
Chromatin remodeling 
HDAC-recruiting 
 
Histone deacetylation, 
ATP-dependent chromatin 
remodeling 
16-kDa nuclear protein 
with intrinsic repression 
domain 
 
 
Coactivators 
(see section 2.3) 
 
 
 
 
 
 
 
 
Coactivators 
 
 
 
 
Coactivators 
 
 
 
Coactivator 
 
 
Coactivators 
 
 
 
Coactivator 
 
Coactivator 
 
Coactivator 
Coactivator 
Basal 
transcription 
machinery 
Coactivators 
 
Coactivator 
 
Coactivator or 
corepressor (see 
section 2.4) 
Coactivator/ 
corepressor 
Corepressors 
 
 
Corepressors 
 
 
Corepressor 
Histone 
acetyltransferases 
(HAT), signal 
integrating 
Acetyltransferases 
for histones and 
other proteins 
 
Histone and CBP 
methyltransferases 
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Corepressor proteins, which are exemplified by NR corepressor (N-CoR) and the 
silencing mediator of retinoid and thyroid receptors (SMRT), play comparable important roles 
by negatively regulating the NR-mediated gene expression (reviewed in (73,74)). N-CoR and 
SMRT are constitutively associated with certain unliganded NRs, particularly NRs of the 
subfamily I such as TR, RARs and VDR, enabling the receptors to actively repress the basal 
transcription in the absence of their cognate ligands (reviewed in (74)). Upon hormone-
binding, corepressor proteins dissociate from receptors and allow the receptors to bind to 
coactivators and activate gene expression of target genes (75). The corepressors do not appear 
to interact with steroid hormone receptors in the absence of ligands. However, they are 
recruited to steroid receptors in the presence of receptor antagonists and mediate release of 
coactivators and transcription repression on receptor target genes (64). This suggests a 
possible existence of a cellular equilibrium of coactivators and corepressors that can be 
favored toward the corepressors in the presence of antagonists, and that has been implicated 
as a mechanism for the antagonist-associated effects of steroid hormone receptors (64). N-
CoR and SMRT have also been demonstrated to confer transcriptional repression on several 
other members of the NR superfamily, including v-ErbA, RevErb, PPAR, and DAX-1 
(Dosage sensitive sex reversal) (reviewed in (76)). 
Coregulator proteins that bind to NRs in a ligand/agonist-dependent manner and have 
mixed coactivator-corepressor functions have also been identified. These include receptor-
interacting protein 140 (RIP140) (77-81) and a recently identified ligand-dependent 
corepressor (LCoR) (82). It has been suggested that these coregulator proteins are involved in 
hormone-dependent repression and in attenuation of agonist-induced transactivation of target 
genes by NRs (66). A brief description of RIP140 and its function in repression of NR-
dependent gene expression is presented in section 2.4. Other proteins that have been 
associated with negative regulation of NR transcriptional activity are the transcriptional 
intermediary protein 1, nuclear receptor-binding SET domain containing protein and the 
small ubiquitous nuclear corepressor (SUN-CoR). SUN-CoR has no homology to N-CoR or 
SMRT and is thought to function as an additional component of the corepressor complex 
involved in transcriptional repression of unliganded NRs (83). 
Corepressor proteins seem not to possess intrinsic repressive activity. Accumulated data 
has suggested that they associate with different classes of histone deacetylase (HDAC) 
factors, becoming part of larger multiprotein complexes which are able to modulate chromatin 
via histone deacetylation and counteract gene activation mediated by HAT-containing 
coactivator complexes (reviewed in (6,63,66,76)). Furthermore, it has been demonstrated that 
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corepressor proteins interact with and inhibit the activity of basal transcription factors (84,85). 
It is also proposed that corepressor binding leads to a masking of the transactivation domain 
of coactivators or inhibition of NR-coactivator interaction (74). 
 
2.2. Structural determinants for the interaction with NRs 
Coactivators have been observed to interact with NRs both at the receptor AF-1 and AF-2 
domain and contribute to modulation of NR-dependent transcriptional activation (reviewed in 
(3)). For example, the transcriptional coactivators TBP, the cAMP response element binding 
protein-binding protein (CBP) and the vitamin D receptor-interacting protein 150 can interact 
with the AF-1 region of GR (86-88). TBP has been also reported to associate with the N-
terminal domain of ERs (89). Most of the AF-1-associated coactivators contain no conserved 
sequence or structural homology, and the structural basis for AF-1-coactivator interactions is 
not well understood. It has been proposed that binding of AF-1 coactivators leads to 
conformational changes at the AF-1 surface (3). Coactivators that have been identified to 
interact with NR at the AF-2 domain (also called AF-2 coactivators) contain conserved 
leucine-rich motifs characterized by the consensus sequence LXXLL (where L is leucine and 
X is any amino acid) and display interaction with the NRs in a ligand-dependent manner (78). 
The LXXLL motif has been shown to be essential and sufficient for the interaction with NRs 
and multiple LXXLL motifs are usually found within a NR-interacting domain of coactivators 
(78,90). Studies on crystal structures of ligand-bound LBD/LXXLL-containing peptide 
complex have suggested that changes in conformation of a NR upon ligand/agonist binding 
create an optimal binding surface for the LXXLL motifs of a coactivator (91-93). 
Similar to coactivators, corepressor proteins contain helical leucine-rich LXXLL motifs or 
LXXLL-related motifs named CoRNR boxes that are required for their interaction with NRs 
(reviewed in (66,76). However, corepressors require different structural determinants on NRs 
for interaction, depending on which subfamily the receptors belong to. In many cases of 
subfamily I NRs, the AF-2 domain is not required for binding to corepressor proteins, but 
rather serves to trigger the dissociation of corepressors from the receptors (6). A domain 
named CoR box which encompasses the hinge region and helix 1 of the LBD of TR and RAR 
is found to be essential for interaction of the receptors with N-CoR (94,95). This interaction 
domain is also noted to be relatively conserved among TR, v-ErbA and RAR, but not among 
other NRs that do not naturally associate with the corepressor. In other cases, the AF-2 helix 
of NRs has been suggested as an important regulator/determinant of coactivator-corepressor 
recruitment exchanges in responses to antagonist-binding, as characterized for PPAR (96). 
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Co-crystallization of antagonist-bound PPAR has demonstrated that in the presence of 
antagonists, the AF-2 domain of PPAR is oriented in a way that forms a binding pocket 
favorable for the binding of corepressor over coactivators. However, mapping of the 
interaction domain of steroid receptors with corepressors has revealed that the receptor 
amino-terminal regions are essential for corepressor interaction (97,98). 
 
2.3. The p160/Steroid receptor coactivator family 
2.3.1. Members and functional domains 
Members of the p160/steroid receptor coactivator (SRC) family include (i) steroid receptor 
coactivator 1 (SRC-1) or nuclear receptor coactivator-1 (NCoA-1) (99), (ii) transcription 
intermediary factor 2 (TIF2) and the mouse homolog glucocorticoid receptor-interacting 
protein (GRIP1) (also termed SRC-2 or NCoA-2) (100,101), and (iii) p300/CBP cointegrator 
protein (p/CIP) (102) and its human homologues: amplified in breast cancer-1 (AIB1) (103), 
activator of the thyroid and retinoic acid receptor (ACTR) (104), thyroid hormone receptor 
activator molecule (TRAM 1) (105),  and receptor-associated coactivator 3 (RAC3) (106) 
(also termed SRC-3 or NCoA-3). The coactivators are genetically distinct but structurally and 
functionally related. They are able to interact with and enhance transcriptional activity of 
multiple NRs ranging from steroid hormone receptors (ER, GR, PR) to non-steroidal hormone 
receptors (TR, RXR, RAR, PPAR) as well as orphan nuclear receptors (HNF-4) in a ligand-
dependent manner (107). 
The p160/SRC members are about 160 kDa in size and share an overall sequence 
similarity of 50-55% and sequence identity of 43-48% (108). The general structure of a 
p160/SRC member has been characterized to contain a highly conserved N-terminal basic 
helix-loop-helix (bHLH)/Per/ARNT/Sim domain (bHLH/PAS), a relatively conserved central 
region (the NR-interacting domain) containing three LXXLL motifs or NR boxes (L1-L3) that 
are responsible for interaction with ligand-bound NRs, and two intrinsic transcriptional 
activation domains (AD1 and AD2) (Figure 3) (107). The AD1 is involved in the interaction 
with HAT-possessing coactivators (CBP/p300). In addition, this domain contains other three 
LXXLL-like motifs (L4-L6) which are required for CBP/p300 interaction and the coactivation 
function of the p160/SRC proteins (102,109,110). AD2 contributes to coactivation of NR-
dependent transcription by participating in the interaction with histone methyltransferases 
(HMT) CARM1 (coactivator-associated arginine methyltransferase 1) and PRMT1 (protein 
arginine methyltransferase 1) (111,112). 
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Figure 3. Structural and functional domains of SRC-1, SRC-2 and SRC-3 (adapted from (108)). Members of 
the p160/SRC family share a common structure containing a basic helix-loop-helix/Per-ARNT-Sim homologous 
(bHLH/PAS) domain, a serine/threonine (S/T) rich region, a NR-interacting domain with three LXXLL 
(encircled L) motifs, and two activation domains AD1 and AD2 which are located to the C-terminal region, 
encompass glutamine-rich sequences (Q) and several other typical or atypical (boxed L) LXXLL motifs. The 
sequence similarity between the p160/SRC members and selected proteins that interact with different domains of 
the coactivators are indicated above and below the bars respectively. 
 
 
A third activation domain (AD3) which is located in the bHLH/PAS domain of GRIP1 has 
been identified. This AD3 enhances transcriptional activation by ER and other NRs through 
recruiting a secondary coactivator known as coiled-coil activator (CoCoA) (113). Moreover 
some parts in the C-terminal region of GRIP1 may regulate its own AD1- and AD2-dependent 
coactivator activity through acting as self-association or repression domains (114). The amino 
acid sequence 1350-1400, named the self-association domain, was thought to mediate 
intramolecular and intermolecular interactions of GRIP1, leading to changes in the protein 
conformation which are favourable or unfavourable for transactivation and coactivation 
activity. The repression domains defined by several sequences of the C-terminal region were 
proposed to modulate the effects of associated corepressor proteins (114). GRIP1 also 
contains an intrinsic corepression domain which is mapped within the amino acid sequence 
765-1007 and responsible for GR-mediated repression at the GR response element tethered to 
the activator protein 1 or the nuclear factor-kappaB (NF-kappaB) (115). 
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2.3.2. Mechanisms of coactivator action 
The carboxyl-terminus of SRC-1 and ACTR/SRC-3 possesses intrinsic HAT properties 
(104,116), which may also be directly involved in chromatin remodeling. However, it is 
believed that p160 family coactivators play central roles in the potentiation of NR-dependent 
transcription by mainly serving as adapters for direct or indirect recruitment of other 
chromatin-remodeling coactivator complexes, including CBP/p300/pCAF (p300/CBP-
associated factor), CARM1/PRMT1, and SWI/SNF (107). Based on accumulated data, a 
general model for the sequential molecular mechanism of p160/SRCs function has been 
proposed (64,117), as illustrated in Figure 4. Briefly, p160/SRC proteins existing in 
complexes with CBP, p300, p/CAF, CARM1 and PRMT1 are first recruited to a target 
promoter through their direct interaction with ligand-activated and promoter-bound NRs. This 
leads primarily to acetylation and methylation of specific histones. The SWI/SNF (Brg/Brm) 
complex is then recruited to promoter-bound NRs through direct or indirect associations with 
CBP/p300, which results in ATP-dependent acetylation of specific histones and subsequent 
changes in local chromatin structure. Recruitment of the TRAP/DRIP complex can occur 
thereafter through interactions with the SRC/CBP/p300 complex or direct interactions with 
NRs. This complex associates directly with the basal transcription machinery and therefore 
initiates transcription. Studies employing chromatin immunoprecipitation (ChiP) assays to 
characterize recruitment of several coregulator proteins by ER to its natural target promoters 
have supported the roles of p160/SRCs as docking or scaffold proteins for the assembly of 
other coactivator complexes at promoter-bound NRs (118-120). These studies have also 
suggested that recruitments of coactivator complexes occur dynamically and in a cyclic 
manner. In addition, the presence of ubiquitin ligases such as E6-associated protein (AP) and 
MDM2 and the 26S proteasome components, which are responsible for specific protein 
degradation (see section 3.4), have been observed in the protein complexes recruited to the 
ER target promoter, suggesting a subsequent downstream proteasome-dependent turnover of 
the receptor-coactivator complex in the transcription activation process (118-120). 
The coactivators of the p160/SRC family are in fact recruited preferentially and 
differentially to promoter-bound NRs in different cellular contexts including promoters, 
ligands and cell types. For example, SRC-1 and SRC-2 exhibit similar, but not identical 
preferences for binding to nine different NRs, of which AR interacts well with SRC-2 but 
poorly to SRC-1 (121). In addition, ER recruits AIB1 and TIF2 differentially to different 
estrogen receptor responsive elements (122). While binding of PPAR to the ligand F-L-Leu 
induces a permissive association with SRC-1 (and p300), binding of the receptor to 
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rosiglitazone preferentially resulted in TIF2 recruitment (123). Moreover, the ligand-induced 
transcriptional activity of PR is modulated primarily by SRC-3 in the luminal epithelium of 
the mammary gland, but primarily by SRC-1 in the stroma compartment of the uterus (124). 
In a recent study where four different thyroid hormone-regulated target genes were examined, 
it has been observed that not only each gene had a different recruitment preference for SRC-1 
and GRIP1, but also the temporal recruitment patterns of SRC-1 and GRIP1 were different 
from gene to gene (125). 
 
 
 
Figure 4. A hypothetical model for the exchange and sequential recruitment of coactivators and 
corepressors in regulation of NR-dependent gene expression (adapted from (117)). In an activated state due 
to ligand binding or other cellular signals, promoter-bound NRs recruit coactivators of the p160/SRC family 
which essentially serve as a scaffold to complex with other coactivator proteins including the histone acetylase 
CBP/p300 and p/CAF(GCN5), and the methylase CARM1/PRMT. The coactivator complexes are involved in 
chromatin remodeling. Following this step is recruitment of the ATP-dependent chromatin remodeler complex 
SWI/SNF (Brg/Brm) and the transcription mediator complex TRAP/DRIP/ARC which make direct contacts with 
the basal transcription machinery to initiate transcription. Association of NRs with the corepressor complexes 
including N-CoR/SMRT leads to transcriptional repression. 
 
 
The molecular basis of NR preferences for coactivators has been linked to the structure of 
the NR with focus on its LBD (125-128) and the NR boxes of coactivators (91,92,121,129-
132). Specific promoter- and/or ligand-binding induces changes in NR structure which 
provide interaction surfaces permissive to certain coactivators but not others. In addition, 
coactivators require different LXXLL-motifs in their interaction with NRs. For instance, 
although NR boxes 2 and 3 display crucial roles for binding of GRIP1 to most NRs, mutations 
in each of these NR boxes differently affected the interactions of GRIP1 with ER and AR or 
GR (121,130). Additionally, LBDs of GR and TR exhibit different affinities for these two NR 
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boxes (91). It is believed that the preferential and differential recruitment of the p160/SRCs 
by specific NRs determines the subsequent assembly of specific downstream coactivator 
complexes on target genes. This has been in part supported by the observation that the 
p160/SRC family members exhibit differential affinities for CBP, whereby CBP interacts 
preferentially with SRC-3 over SRC-1 and SRC-2 (102). Furthermore, it has been 
demonstrated that upon ligand binding PR interacts preferentially with SRC-1 which leads to 
recruitment of CBP and an enhanced acetylation of histone H4. In contrast, GR prefers 
interaction with SRC-2 and subsequently recruit pCAF which results in enhancements of 
specific acetylation, hypomethylation and phosphorylation of histone H3 (128). 
 
2.3.3. Expression profile and biological roles 
The members of the p160/SRC family are widely expressed and have been detected in several 
tissues including placenta, testis, pancreas, lung, kidney, liver and brain. However, the relative 
expression level of each coactivator member as well as among the coactivators varies between 
cell types and tissues (reviewed in (107,108)). For example, mouse SRC-3 is predominantly 
expressed in epithelial cells of mammary gland, oocytes, vaginal epithelial layer, hepatocytes 
and in the smooth muscle cells of blood vessels, intestines and oviducts (133,134). SRC-1 is 
expressed at a higher level than SRC-2 and SRC-3 in the cerebella Purkinje cells (PCs) (135). 
While the overlapping distribution of the p160/SRC members in various tissues implies 
possible functional redundancies between the coactivators, their variable tissue-specific 
expression suggests that each member of the family may exhibit differential and preferential 
biological functions in certain cell types/tissues with certain receptors. 
The biological importance of the p160/SRC family members have been partially 
characterized by gene-ablation studies performed in mice, as reviewed in ref (108). Specific 
phenotypes observed in mice lacking either of the genes encoding the coactivators are 
summarized in Table 4. Particularly, SRC-1 is implicated in mediating actions of steroid 
hormones via the transcriptional activity of steroid hormone receptors (136,137) and is 
required for thyroid hormone-dependent downregulation of thyroid stimulating hormones 
(138). SRC-1 plays also pivotal roles in brain development and function, as well as in 
regulation of energy metabolism (135,139). SRC-2/GRIP1 has major roles in reproduction, 
lipid metabolism and energy balance (139,140). However, SRC-1 and GRIP1 seems to be 
differently involved in the regulation of energy homeostasis, as evidenced by different 
phenotypic outcomes of SRC-1 and SRC-2 knock out mice (Table 4). Interestingly, the 
expression level of GRIP1 in both brown (BAT) and white (WAT) adipose tissues, as well as 
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the expression ratio between SRC-1 and GRIP1 is enhanced in mice that are subjected to a 
high fat diet (139). The recent identification of significant downregulation in gene expressions 
of several key regulatory enzymes of energy metabolism upon ablation of GRIP1 gene has 
strengthened the pivotal roles of GRIP1 in energy homeostasis (141). Unlike the other two 
members, SRC-3 is critically important for cellular growth and female reproductive function 
and development (133,142). SRC-3 is also essential for vascular cell proliferation and 
inflammatory and immune responses (134,143). Notably, SRC-3 mRNA is expressed at 
extremely high levels in ER-positive breast and ovarian tumors and cancer cell lines 
(reviewed in (108)), suggesting a potential role of SRC-3 in development of breast 
carcinogenesis. Altogether, the observations have indicated that the p160/SRC members 
possess a functional specificity and play important roles in different biological processes, 
especially reproduction and metabolism. 
 
Table 4. The Major Phenotypes Observed in p160/SRC Knockout (KO) Mice. 
 
KO mice Phenotypes 
 
References 
 
SRC-1 
 
Normal growth and fertility; partial steroid and thyroid resistance; 
delayed development of cerebellar PC; moderate motor learning 
dysfunction; no effect on PPAR-regulated genes in liver; impaired 
thermogenesis and decreased energy expenditure in brown fat 
 
 
(135-139) 
SRC-2 Normal somatic growth; defective spermatogenesis; testicular 
degeneration; placental hypoplasia; reduced fertility in both male and 
female; lower fat accumulation and higher lipolysis in white adipose 
tissue; higher energy expenditure in brown adipose tissue; resistance to 
obesity 
 
(139-141) 
SRC-3 Somatic growth retardation; delayed growth of puberty and mammary 
gland; lower levels of IGF-1 and estrogen; reduced female fertility; 
reduced ER-dependent vascular protection; impaired expression of 
interferon-regulatory factor 1 by NF-kappa B 
 
(133,134,142,143) 
 
 
2.4. Receptor-interacting protein 140 
The receptor interacting protein 140 (RIP140) was originally identified and characterized as a 
coactivator that interacts with ER and enhances ER-mediated transcriptional activation in an 
estrogen-dependent manner in breast cancer cells (77). However, the function of RIP140 in 
NR-dependent regulation of gene expression is far more complex since several subsequent 
studies have demonstrated that RIP140 binds to and inhibits the transcriptional function of 
several NRs including TRs, PPARs, RARs, RXRs, GR and AR in the presence of the receptor 
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cognate ligand/agonist (79-81,144,145). The structure of RIP140 (Figure 5) consists of 10 
leucine-rich motifs (nine LXXLL motifs and a tenth LYYML motif) that allow its interaction 
with the LBD of NRs (78,102,146) and four autonomous repression domains (RD1-4) that are 
implicated in recruitment of histone- or DNA-modifying enzymes capable of repressing 
transcription (147). 
RIP140 binds to nuclear receptors in a ligand-dependent manner by a mechanism similar 
to that of the p160/SRCs. The LXXLL motifs of RIP140 dock into a cleft formed by the AF-2 
of NRs upon hormonal ligand binding (78,102). Individual LXXLL motifs of RIP140 allow 
the coregulator to exhibit selective binding to NRs (146,148,149). Particularly, the coregulator 
LXXLL-less motif 10 interacts preferentially with retinoid receptors (146). Moreover, RIP140 
NR boxes also exhibit differential bindings to NRs as either constitutive or ligand-induced 
binding (150). 
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Figure 5. Schematic illustration of RIP140 with its functional domains (edited from (151)). RIP140 is 
composed of 1158 amino acids, contains nine LXXLL motifs (1-9, black bars) and one LXXLL-less motif (10, 
the dark grey bar). The coregulator also possesses four repression domains (RD1-4). The regions responsible for 
binding to selected proteins (histone deacetylase HDAC; C-terminal binding protein CtBP) are also indicated. 
The white bars represent the interaction sequence/motif for the CtBP. 
 
 
Evidence has indicated that RIP140 represses transcriptional activity of NRs by competing 
with coactivator proteins for binding to the receptor AF-2 domain. RIP140 antagonized SRC-
1-mediated coactivation of NRs (81). The repressive effect of RIP140 on GR transactivity 
was partially overcome by an increased expression of TIF2 (144). In addition, Chen and 
coworkers (152) demonstrated that RIP140 strongly competed with pCAF for ligand-
dependent interaction with RAR/RXR both in vitro and in vivo. Furthermore, studies 
employing ChiP assays demonstrated a rapid recruitment of RIP140 followed by a delayed 
recruitment of pCAF to RAR- and TR-target promoters in cells after treatment with retinoic 
acid (153). 
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RIP140 also acts as a negative regulator of NR transcriptional function through recruiting 
chromatin-deacetylating HDACs. The coregulator RD1 has been reported to bind to HDAC 1 
and 3 of class I (154,155) and class II HDAC5 (156), while RD2 binds to the C-terminal 
binding protein (CtBP) that then recruits HDAC enzymes (157,158). Disruption of interaction 
with CtBP has been shown to result in loss of transcription repression by RIP140 (157). In 
addition, it has been observed that the ability of RIP140 to inhibit the transcriptional activity 
of retinoic acid receptors in transfected cells is reversed by treatment with trichostatin A 
(TSA), a HDAC inhibitor (154). Moreover, the presence of RIP140 has been demonstrated to 
be required for retinoid acid-induced recruitment of HDACs to ligand-bound RAR/RXR and 
associated with a decrease in histone acetylation on the promoter of RAR as well as TR target 
genes (150,155). 
RIP140 is detected in most tissues albeit localized in specific cell types where its 
expression is controlled hormonally or developmentally (159-161). High expression levels are 
found in the gonads (160) and metabolic tissues including adipose tissue, liver and muscle, 
where the highest level of RIP140 mRNA is found in WAT, followed by skeletal muscle, 
BAT and liver (161). During the follicle maturation process, RIP140 expresses increasingly 
from no detectable expression in the granulosa cells of the primary follicles to high expression 
in the outer mural cells of the pre-ovulatory follicles (160). The expression level of RIP140 is 
also significantly increased during the process of adipocyte differentiation (161,162). 
Hormones that regulate RIP140 expression include estrogen (163), retinoid acid (164), 
progestin (165), and vitamin D (166). 
Consistent with its expression profile, studies with RIP140 ablation in mice or RIP140 
depletion by siRNA in cell models have revealed important roles of the coregulator in female 
reproduction and metabolic regulation (reviewed in (151,167)). Briefly, female mice devoid 
of RIP140 exhibit complete infertility due to failure of ovulation (159). RIP140-null mice 
have lower body weight in both males and females as a result of reduced fat accumulation in 
WAT, resistance to diet-induced obesity and hepatic steatosis and increased insulin sensitivity 
upon challenging with high fat diet (161,168). Analyses of gene expression in adipocytes 
from RIP140-null mice have shown that RIP140 suppresses expression of several genes 
encoding key proteins involved in energy metabolism in adipocytes (169), as well as in 
catabolic pathways for carbohydrates and fatty acids such as tricarboxylic acid cycle, 
glycolysis, fatty acid oxidation, oxidative phosphorylation and mitochondrial biogenesis 
(168). 
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3. Regulation of nuclear receptor coregulators 
NRs and coregulators are subjected to posttranslational modifications (phosphorylation, 
acetylation, methylation, sumoylation and ubiquitination) or degradation processes which 
modulate their transcriptional function (reviewed in (64,170-174)). Posttranslational 
modifications may regulate the coregulator enzymatic activity, its interaction with NRs and/or 
other transcription factors, its protein stability and subcellular localization (Figure 6). 
Degradation processes modulate coregulator availability for the interaction with NRs. 
Regulation of coregulators is implicated as a mechanism for controlling NR-dependent gene 
transcription in response to cellular signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Posttranslational modifications of coactivators and corepressors. Coactivators and corepressors 
can be postranslationally modified by acetylation, methylation, phosphorylation, sumoylation and ubiquitination 
in response to extracellular signals. Posttranslational modifications regulate the subcellular localization of 
coregulators, their interactions with NRs and other transcription factors, and their turn-over via degradation. 
 
 
3.1. Intracellular signaling pathways 
Eukaryotic cells possess many protein kinases that mediate the cellular responses to 
extracellular stimuli such as hormones. Among them are the cAMP-dependent protein 
kinase/Protein kinase A (PKA) (175) and the members of the mitogen-activated protein 
kinase (MAPK) family such as the extracellular signal-regulated kinases (ERKs) and the p38 
MAPKs (reviewed in (176)). PKA mediates cellular responses to an elevated intracellular 
level of cAMP (see section 3.2 for more details). The kinases of the MAPK family are 
activated by several stimuli including growth factors and cytokines (176). PKA as well as 
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MAPKs have been implicated in the regulation of NR transcriptional activity mainly by 
phosphorylation of the receptors (reviewed in (14,170,171)). 
 
3.2. The cAMP/PKA signaling pathway 
The cAMP/PKA signaling pathway is activated by a number of hormones such as the 
pituitary glycoprotein hormones (ACTH, FSH, LH, and TSH (thyroid stimulating hormone)) 
(177,178), glucagon and adrenaline. The hormones bind to ligand-specific G protein-coupled 
receptors (GPCRs) located at the plasma membrane and activate adenylyl cyclase (AC) which 
catalyses the conversion of ATP to the second messenger cAMP. As a result, the intracellular 
level of cAMP is increased, followed by activation of several downstream kinase signaling 
cascades including the PKA pathway (Figure 7). For details about the other main targets of 
cAMP, it is referred to reviews (39,179,180)). The intracellular level of cAMP is controlled 
by phosphodiesterases which convert cAMP to 5’-AMP. 
PKA is the classical effector of cAMP. In an inactive state, the PKA holoenzyme is 
composed of two regulatory (R) and two catalytic (C) subunits, and is localized in the 
cytoplasm. There are different isoforms of PKA which are determined by the composition of 
their regulatory (RI, RI, RII, RII) and catalytic (C, C, C) subunit isoforms. PKA is 
activated upon binding to cAMP at its R subunits, which in turn leads to dissociation and 
release of the C from the R subunits. In a released and free form, the catalytic subunits 
phosphorylate target proteins and are able to translocate into the nucleus through passive 
diffusion (Figure 7). 
PKA mediates cAMP responses to gene transcription via phosphorylation and activation 
of the cAMP-response element binding protein (CREB) (181). While the mechanisms for 
PKA-induced regulation of gene transcription by NRs are still to be elucidated, it has been 
well established that CREB is the main key mediator of PKA signaling in transcriptional 
regulation. CREB is phosphorylated by PKA at serine residue Ser-133, which in turn induces 
transcriptional activation of numerous functional genes important for various cellular 
processes (182). 
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Figure 7. Activation of the cAMP signaling pathway. Hormone binding to the G-protein coupled receptor 
(GPCR) activates the adenylyl cyclase (AC) which catalyses the conversion of ATP to cAMP. Elevation of 
cAMP activates PKA and can also modulate other signaling components such as the exchange protein directly 
activated by cAMP (EPAC) and ion channels. Kinase-active catalytic subunit (C) diffuses into the nucleus, 
phosphorylates CREB and may modulate NRs and NR coregulators (NCo). Simplified signaling cascades 
induced by growth factors and cytokines via MAPKs (p38 and ERK) which may be modulated by PKA and are 
implicated in regulation of NRs and coregulators are also included. (151,176,179,183,184). 
 
 
3.3. Regulation by protein phosphorylation 
Phosphorylation has been observed on coactivator proteins, especially the p160/SRCs, in 
responses to growth factors, steroid hormones, cytokines, and activation of different protein 
kinase pathways (reviewed in (185)). SRC-1 possesses at least seven phosphorylation sites 
(Ser 372, 395, 517, 569, 1033, 1179 and 1185) with consensus sequences for the serine 
threonine-proline directed family of protein kinases as well as ERKs of the MAPK family 
(186). SRC-1 can be phosphorylated in vitro by ERK-2 (186) and elevation of intracellular 
cAMP level in cells has been shown to induce phosphorylation of SRC-1 at two mitogen-
activated protein kinase (MAPK) sites, threonine 1179 and serine 1185 (187). GRIP1/SRC-2 
is phosphorylated at a specific site Ser-736 in vitro by ERK and in vivo by p38 of the MAPK 
family in response to EGF (188,189). In vitro phosphorylation of GRIP1 by c-Jun N-terminal 
kinase 1 through sites other than Ser-736 and Ser-554 has also been observed (188). 
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Similarly, studies have identified AIB-1/SRC-3 as an in vivo phosphoprotein with six 
phosphorylation sites (Thr-24, Ser-505, 543, 857, 860 and 867) (190,191). Several protein 
kinases including MAPK (190,191), PKA (191), the receptor tyrosine kinase HER2 (human 
epidermal growth factor receptor 2) (192,193), as well as inhibitor kappa B kinase (IKK) of 
the cytokine TNF- (the tumor necrosis factor  (TNF-) signaling pathway (143,191) have 
been demonstrated to phosphorylate SRC-3. Phosphorylation induced on other NR coactivator 
proteins including CBP/p300 by the mitogen-activated/extracellular response kinase kinase 1 
(MEKK1) and AMP-kinase (194,195), and PGC- by p38 kinase (196) have also been 
observed. 
In many cases, phosphorylation of coactivators have been shown to induce an 
enhancement in gene transcription mediated by NRs (143,186-190,194,196). For example, 
phosphorylation of SRC-1 increases its ability to coactivate progesterone- or cAMP-
dependent transcriptional activation of PR-target genes (187), and interleukine-6-dependent 
transactivity of AR (197). Mutation of the Ser-736 phosphorylation site of GRIP1 to Ala was 
observed to decrease EGF-induced GRIP1 coactivation function in PR- and ER-mediated 
gene transcription (188,189), while mutational disruption of SRC-3 phoshorylation was 
demonstrated to reduce SRC-3 activity on ER, AR as well as NF-kappa B (191). Conversely, 
phosphorylation of coactivators can negatively regulate their function, as evidenced by the 
observation demonstrating that phosphorylation of p300 on Ser-89 by the protein kinase C 
reduces its coactivity as well as its HAT activity (198). Thus, phosphorylation of coactivators 
seems to play an important role in mediating cellular signaling to regulation of transcriptional 
responses of NR-target genes. In addition, it has been proposed that posttranslational 
modifications provide a molecular determinant for the ability of p160/SRCs to distinguish 
among different NRs and other transcription factors to allow specific responses to distinct 
upstream signaling pathways (185). 
Although the actual underlying mechanism for regulation of NR-mediated gene 
transcription by coactivator phosphorylation remains to be elucidated, certain evidence has 
indicated that physical or functional interactions of coactivators with NRs and other 
transcription factors are affected by phosphorylation events. Mutational disruption of selected 
MAPK-phosphorylated sites (Ser 1179 and 1185) of SRC-1 leads to a reduction in its 
interaction with p300/CBP-associating factor (p/CAF) and a loss of its functional association 
with CBP (187). MAPK activation increases interaction of AIB-1/SRC-3 with p300 and 
associated histone acetyltransferase activity (190). Importantly, phosphorylation of SRC-3 
selectively affects its ability to interact with steroid receptors (ER, AR) and CBP, but not 
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CARM1 (191). AMP kinase-induced phosphorylation of p300 dramatically reduces its 
interaction both in vitro and in vivo with a range of NRs including PPAR, TR, RAR and 
RXR (195). Coactivator phosphorylation may also influence its subcellular localization, as 
supported by the observation that TNF-induced phosphorylation of SRC-3 correlates with an 
increased nuclear import of SRC-1 in cells (143). This is confirmed by another observation 
where treatment of serum-starved cells with growth factors or phorbol esters, which can 
phosphorylate p/CIP (SRC-3) (190,192,193), promotes p/CIP translocation into the nucleus 
(199). Likewise, cytokine or lipopolysaccharide-induced phosphorylation of PGC-1 by p38 
kinase leads to an increase in stability and activity of the coactivator (196). Taken together, it 
seems that phosphorylation of NR coactivators regulates various aspects of their function, 
including their protein-protein interactions, stability and subcellular localization. 
Corepressor proteins have also been observed as targets for phosphorylation elicited by 
MAPK-mediated signaling pathways (200-202). A proteomic analysis of RIP140 has 
identified 11 phosphorylation sites of which 5 sites are located in the N-terminal repression 
domain RD1 (202). Further characterization of the RD1 phosphorylation, which is induced by 
MAPK, and mutational analyses of the phosphorylation sites in this domain have indicated 
that phosphorylation enhances RIP140 repressor function through increased recruitment of 
HDACs (202,203). Another study has reported that phosphorylation of RIP140 regulates its 
interaction with the 14--3-3 protein, which is able to export the coregulator out of the nucleus 
and alter its intranuclear localization, resulting in an enhancement of GR-induced 
transactivation (204). The corepressor SMRT is found as phosphoprotein in vivo, and may be 
phosphorylated by several protein kinases including the MEK1, MAPK and MEKK1 kinases, 
resulting in its dissociation from the NRs, relocation from nucleus to the cytoplasm, and a 
reduction of the corepressor function (200,201). Similarly, phosphatidylinositol-3-OH 
kinase/Akt1 kinase-dependent phosphorylation of N-CoR complex results in a temporally 
correlated redistribution of N-CoR to the cytoplasm (205). The nuclear to cytoplasm shift of 
RIP140 or SMRT and N-CoR mediated by phosphorylation may contribute to positive 
regulation of NR-mediated gene expression by reducing the level of corepressor proteins in 
their functional compartment. Interestingly, it has been shown that N-CoR is non-responsive 
to MEKK1-induced phosphorylation and all of the subsequent forms of regulation detected on 
SMRT, but it responses similarly as SMRT to other downstream signal transduction pathways 
mediating the effects of EGF/cytokines (201). This suggests that NR coregulator proteins may 
be differentially selected for regulation by particular signaling pathways. 
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3.4. The ubiquitin proteasome-mediated degradation pathway 
The ubiquitin-proteasome proteolytic pathway represents a major cellular process for 
selective and specific degradation of proteins in eukaryotic cells. The process involves two 
discrete and successive steps: i) covalent attachment/modification of the substrate with 
multiple ubiquitin molecules and ii) degradation of the modified protein by the 26S 
proteasome complex. The biochemical steps and the components involved in these processes 
have been reviewed in detail elsewhere (206). Following is a brief description of the pathway. 
 
3.4.1. The ubiquitination system 
Ubiquitin (Ub) is a highly evolutionarily conserved polypeptide of 76 amino acids. 
Conjugation of Ub molecules to target proteins/substrates (S), known as ubiquitination, is a 
multi-step process which involves three different types of enzymes (Figure 8). Ubiquitin is 
activated in an ATP-dependent manner by the ubiquitin-activating enzyme E1, to generate a 
high-energy thiol ester intermediate E1-S-Ub. The activated ubiquitin moiety is then 
transferred to one of the several ubiquitin carrier/conjugating enzymes E2 (UBCs) forming 
another high-energy thiol ester intermediate E2-S-Ub. The E2 enzyme then transfers the 
ubiquitin to a lysine residue in the target substrate/protein which is specifically bound to a 
member of the third enzyme E3 family named ubiquitin-ligase. The ubiquitin transfer from E2 
to the substrate occurs either directly of indirectly depending on the type of the substrate-
bound E3 enzyme (206). A polyubiquitin chain is synthesized and elongated by successive 
attachments of activated ubiquitin molecules to an internal Lys residue of the previously 
substrate-conjugated ubiquitin moiety. This process seems to be promoted by an ubiquitin 
chain elongation factor called E4 (207). The polyubiquitin chain-conjugated substrate is 
recognised by the downstream 26S proteasome complex and targeted for degradation (Figure 
8). In vitro evidence has suggested that targeted substrates need to be conjugated with 
polyubiquitin chains of at least 4 ubiquitin moieties in length to be recognised and degraded 
by the 26S proteasome (208). 
More E2 than E1 and even more E3 enzymes have been identified in eukaryotes, as so a 
single E1 enzyme activates ubiquitin for an array of E2 ubiquitin conjugating enzymes, and 
each E2/UBC is able to catalyse ubiquitin transfer reaction to substrates for a number of E3 
enzymes. Eleven ubiquitin carrier/conjugating enzymes in yeast (Ubc1-8, 10, 11, 13) (206) 
and over 40 different potential UBCs in the human genome (designated as UbcH followed by 
variable numbers) (209) have been identified. Although there are several hundreds of 
heterogeneous E3s (209), many of them can still be classified into two major groups named 
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the HECT (Homologous to the E6-associated protein/E6-AP C Terminus) domain- and the 
RING (Really Interesting New Gene) finger-containing E3s. E2/UBC enzymes transfer the 
activated ubiquitin indirectly to the substrate of the HECT domain E3 by first attaching the 
ubiquitin to the E3 which subsequently transfers the ubiquitin to the substrate. In contrast, the 
RING finger E3 ligases catalyse a direct transfer of the activated Ub moiety from the E2-S-Ub 
intermediate to the E3 ligase-bound substrate. In addition, the identification of E4 enzyme has 
defined a novel protein family, designated as U box, which is a derivative of the RING finger 
E3 family (reviewed in (206)). 
 
3.4.2. The 26S proteasome system and protein degradation 
The 26S proteasome system is a multisubunit protein complex which is highly conserved 
among all eukaryotes. The complex is composed of a 20S catalytic core particle sandwiched 
between two 19S regulatory particles (Figure 8). The 19S regulatory particle contains at least 
18 different subunits and possesses ubiquitin hydrolysis activity. This particle serves multiple 
roles in regulation of the proteosomal activity including substrate selection, substrate 
preparation for degradation, translocation of substrate into the 20S core, and dictation of the 
end products after digestion of the substrate protein. In mammalian cells, another regulatory 
complex named 11S (or REG) regulator or PA28 which binds to the ends of the proteasome 
core 20S and activate its peptidase function in protein antigen presentation has been identified 
(210). The 20S has a barrel-shaped structure which is made up of four rings (two  and two  
rings) of seven subunits each. While the -rings are non-catalytic and facing outside, the two 
inner -rings have proteolytic active sites with different specificities facing inward into a 
sequestered proteolytic chamber. With this structure, the 20S proteasome core is able to block 
random degradation and provide a high level of substrate specificity (206). 
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Figure 8. The ubiquitin proteasome-mediated degradation pathway. Ubiquitin (Ub) is activated in an ATP-
dependent manner by an ubiquitin activating enzyme E1. The activated Ub moiety is then transferred to one of 
several ubiquitin- carriers or conjugating enzymes (UBC or E2). A specific ubiquitin ligase E3 (HECT or RING) 
which is bound to the target protein catalyzes direct or indirect transfer of the activated ubiquitin molecule to the 
target protein. Polyubiquitination is achieved through successive additions of activated ubiquitins to the 
previously attached ubiquitin moiety. Polyubiquitinated proteins are recognized and degraded by the 26S 
proteasome complex. The attached Ub moieties are released and recycled (206). 
 
 
3.4.3. Signals and modes of substrate recognition 
The specificity for substrate recognition and degradation by the 26S proteasome is determined 
by the E3 ubiquitin ligase alone or in combination with the E2 conjugating enzyme (206). 
Based on accumulated data, several modes of specific substrate recognition by E3 ligases 
have been reported (reviewed in (206). Some ubiquitin ligases recognise and bind to their 
protein substrates simply via the substrate NH2-terminal residue which is, in this case, referred 
to as the “destabilizing residue”. Likewise, a number of protein substrates of the ubiquitin-
proteasome proteolytic pathway are subjected to phosphorylation before their ubiquitination. 
This modification in certain cases is necessary for direct recognition of the modified protein 
by an appropriate E3 ligase. Particularly, several target proteins are recognised indirectly by 
their specific E3 ligases via ancillary proteins which bind to target proteins. For example, GR 
is degraded after complex formation with the carboxyl terminus of Hsc70-interacting protein 
(CHIP) and the chaperon proteins Hsp70 and Hsp90 (211). It has also been noted that many 
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rapidly degraded proteins contain short hydrophilic stretches of at least 12 amino acids 
enriched in proline, glutamic acid, serine, and threonine (known as PEST motifs), which in 
several cases seem to contain phosphorylation sites required for degradation (212). In 
addition, the destruction box represented by the consensus sequence R-A/T-A-L-G-X-I/V-
G/T-N (absolutely conserved residues are marked in bold) is an important degradation signal 
for certain proteins especially cell-cycle regulators. Thus, degradation signals are inherent in 
the primary protein structure of the substrate as specific sequences or motifs which can be 
modified and/or recognised directly or indirectly by the E3 ligase. 
 
3.5. Regulation by ubiquitination and degradation 
The role of the ubiquitin-proteasome pathway as an integral component in NR-mediated gene 
transcription has been discussed since several proteins/enzymes associated with the ubiquitin-
proteasome degradation pathway were identified as coactivators (such as UbcH5 and 7, E6-
AP and RPF1/NEDD4 of E3 enzyme group, and subunits of the 26S proteasome complex) or 
corepressor (e.g. the ubiquitin ligase BRCA1) of NRs (reviewed in (213,214). Several reports 
have demonstrated that liganded-NRs (ER, GR, PR, TRs, PPAR, RARs and RXRs) and 
unliganded-NRs (AR, VDR and PPAR) are ubiquitinated and degraded by the ubiquitin-26S 
proteasome pathway (reviewed in (213,214)). In certain cases, treatment with proteasome 
inhibitors has been observed to lead to an increase in the receptor level, but inhibition of the 
receptor transcriptional activity (215-217). This signifies that receptor turnover is required for 
its efficient transcription. Furthermore, enzymes of the ubiquitin-proteasome pathway are 
recruited to the promoters of NR-target genes (120,218,219). This strengthens the importance 
of the ubiquitin-proteasome pathway in transcriptional regulation by NRs. 
Regulation of NR coactivators and corepressors through proteasomal degradation has 
been documented. GRIP1 was first found to colocalize with components of the 26S 
proteasome including the 20S proteasome core, PA28 and ubiquitin in discrete nuclear foci 
(220). Later, the coactivator together with the other two members of the p160 coactivator 
family, SRC-1 and RAC3/SRC-3, as well as CBP have been demonstrated to be targets for 
degradation via the ubiquitin-proteasome pathway (215,220,221). However, degradation of 
individual p160/SRCs is stimulated by different UBC enzymes in vitro (221). SRC-1 is 
degraded by UBC2. Likewise, TIF2/GRIP1 degradation requires UBC5, 7 and 8, and 
degradation of RAC3/SRC-3 is dependent on UBC2, 3, 4 and 5. Interestingly, a recent study 
has reported that the steady-state level or turn-over of SRC-3 is also regulated by the REG-
proteasome (20S) machinery in an ubiquitin- and ATP-independent manner (222). REG 
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which is a proteasome activator of the 11S family known to stimulate the trypsin-like activity 
of the 20S proteasome interacts with and enhances degradation of SRC-3, leading to 
modulation of the ER-dependent transcription activity. Another example of regulation of 
coactivators by the ubiquitin proteasome-mediated degradation pathway is the observation 
that p/CAF stability is decreased by the E3 ubiquitin ligase MDM2 of the RING domain 
family through ubiquitination and protein degradation (223). Similar effects of the 
proteasomal pathway on NR corepressor proteins including N-CoR have also been reported 
(224). 
Ubiquitin proteasome-mediated degradation has been proposed as a mechanism for 
selectively removing corepressors and/or coactivators after they have fulfilled their roles, 
clearing the way for subsequent recruitment of other coregulators to the promoter-bound NR, 
and allowing transcription reinitiation and attenuation (65). In line with this, the transducin -
like 1(TBL1) and its homologous protein TBLR1, which are components of the E3 ubiquitin 
ligase complexes, have been shown to essentially participate in gene transcription by liganded 
NRs by serving as specific adapters for the recruitment of the proteasome components, 
mediating the dissociation of the N-CoR corepressor complex and its subsequent degradation 
(225). This process is believed to mediate a required exchange of corepressors for 
coactivators upon ligand binding. Moreover, proteasomal degradation of NRs and their 
coregulators could induce dissociation of the initiation complex and facilitate the assembly of 
a productive elongation complex (226,227). 
 
3.6. Regulation by other posttranslational modifications 
Coactivators and corepressor are also subjected to regulation through other forms of 
posttranslational modifications. Protein acetylation by transcriptional coactivators possessing 
acetyltransferase activity including the p160/SRCs and CBP/p300, as well as protein 
methylation by methyltranferases CARM1 and PRMT1 in NR-mediated transcription was 
originally directed solely toward histones. However, an increasing number of reports have 
demonstrated that coactivators are able to posttranslationally cross-modify one another 
resulting in changes in coregulator association with NRs. Particularly, p300/CBP has been 
reported to acetylase ACTR/SRC-3 on lysine residues adjacent to an NR box, leading to 
disruption of the association between this p160 coactivator and the promoter-bound ER and 
subsequent attenuation of gene transcription (228). Acetylation of RIP140 by p300/CBP 
which reduces RIP140 interaction with CtBP has also been observed (157). By this 
observation, the authors have proposed that acetylation-mediated disruption of corepressor 
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interaction may serve as a mode of transcriptional activation. A recent proteomic analysis has 
identified eight acetylated lysines in RIP140 that might be important for the coregulator 
repressive function and subcellular localization (203). While CBP is able to induce acetylation 
on several coregulator partners, its own coactivator function has been found to be regulated 
through methylation by CARM1 (229,230). In one case, CARM1 has been shown to 
methylate an arginine (Arg) residue within the KIX domain of CBP, leading to inhibition of 
its interaction with the transcription factor CREB (cAMP-response element binding protein) 
(229). This is thought to increase the CBP pool available for interaction with NRs and 
therefore could promote CBP coactivation of NR activity (64). In another case, CARM-1-
induced methylation of CBP at arginine residues Arg-714, 742 and 768 in another conserved 
region has been reported to be essential for the cooperative coactivator function of CBP with 
GRIP1 on NRs as well as for steroid hormone-induced gene activation (230). Interestingly, a 
recent study by O’Malley group (231) has demonstrated that the p160 member SRC-3 is also 
methylated by CARM1 at an arginine located in its CARM1 binding region, and this 
methylation is associated with inhibition of ER-dependent transcription via promoting 
dissociation between SRC-3 and CARM1. 
Coregulators are also regulated by sumoylation which does not promote coregulator 
protein degradation, but seems to modulate coregulator protein-protein interaction and 
localization. The NR-interaction domain of both GRIP1 and SRC-1 can be modified by 
sumoylation (232,233). GRIP1 sumoylation sites have been shown to be essential for its 
colocalization with AR in the nucleus after testosterone treatment and for its coactivator 
function on AR-dependent gene transcription (232). Likewise, sumyolation of SRC-1 has 
been demonstrated to enhance PR-SRC-1 interaction and prolong the retention of SRC-1 in 
the nucleus (233). 
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AIMS OF THE PRESENT STUDY 
 
The purpose of this work was to characterize the role of selected nuclear receptor coregulator 
proteins with a special focus on protein-protein interactions and cAMP-dependent protein 
kinase signaling pathways. The main objectives of the present thesis were: 
 
1. To characterize the roles of the receptor-interacting protein (RIP) 140 in regulation of 
Steroidogenic factor 1 (SF-1)-mediated transcriptional activation 
 
2. To identify interactions between SF-1 and nuclear receptor coactivators, and to 
examine the role of cAMP-dependent protein kinase in regulation of the Steroid 
receptor coactivators TIF2/GRIP1 and p/CIP 
 
3. To characterize the roles of cAMP and cAMP-element binding protein (CREB) in the 
regulation of TIF2/GRIP1 coactivator function.   
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GENERAL DISCUSSION 
1. Regulation of SF-1-dependent gene transcription 
Since its isolation in the early 1990s by two independent laboratories (10-13), the orphan 
nuclear receptor SF-1 has emerged more and more evident as an essential regulator of 
endocrine development and function at multiple levels of the hypothalamic-pituitary-
steroidogenic axis. Particularly, SF-1 regulates the transcriptional expression of several 
pivotal enzymes involved in the steroid hormone biosynthesis (14). The number of genes 
potentially regulated by SF-1 is rapidly growing. However, knowledge of the molecular 
mechanism underlying the regulation of gene expression by SF-1 is still limited. The basic 
molecular mechanism for activation and regulation of steroid hormone receptors or many of 
the non-steroidal NRs such as TR, RXR and RAR, has been relatively well characterized (6). 
Ligand-binding is essential for initial activation of these NRs, and the magnitude of their 
transcriptional activities relies on their virtual interaction with coactivator or corepressor 
complexes (62,63,234). Ligand-binding leads to changes in NR conformation which allows 
the NR to recruit coactivator complexes or exchange corepressors with coactivators necessary 
for transactivation of target genes (62,64). Less has been known about the association 
between orphan NRs, particularly SF-1, and coregulator proteins. 
 
1.1. Regulation of SF-1 by RIP140 
RIP140 has been reported to interact with SF-1 as well as DAX-1 and represses both the basal 
and cAMP-induced transactivity of SF-1 from the promoter gene encoding human 
Steroidogenic acute regulatory protein (StAR) (235). Our findings (Paper I) have 
demonstrated that RIP140 also interacts with SF-1 in an AF-2 dependent manner. The 
interaction involves multiple LXXLL motifs of RIP140, of which the region containing four 
C-terminal LXXLL motifs exhibits the strongest interaction. A similar case has also been 
observed with PPAR whose interaction with RIP140 is mediated predominantly by multiple 
LXXLL motifs in the C-terminal 728 amino acids of RIP140 (81). However, both the amino-
terminal and carboxyl-terminal fragments of RIP140 interact equally well to GR (204). 
Preferential use of LXXLL motifs by RIP140 for the interaction with other NRs (RAR, RXR 
and TR) has also been reported (146,149,150). Together, these studies support the fact that the 
number and the sequences including the flanking sequences of LXXLL core motifs contribute 
to the affinity and selectivity of RIP140 for different NRs (148). 
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RIP140 appears to function as a repressor of SF-1 ((235), Paper I) through different 
mechanisms. RIP140 represses SF-1 transactivity by antagonizing the stimulatory functions of 
TIF2 and p/CIP, as well as by association with histone deacetylases (HDACs) as evidenced by 
the partial inhibition of RIP140 repressive function upon treatment with the HDAC inhibitor 
TSA (Paper I). The fact that RIP140 acts as a negative coregulator of certain NRs such as 
PPAR and GR through competition with the p160/SRCs for receptor binding has previously 
been reported by others (81,144). Recently, RIP140 has also been reported to compete with 
p/CAF for binding to RAR (152,153). In addition, RIP140  interacts directly with several 
HDAC enzymes of both class I and II (154-156), that are able to deacetylate chromatin, 
leading to transcription repression. While the HDAC activity seems to be necessary for 
RIP140-mediated repression of RARs and TRs (150,155), HDAC inhibition by TSA has no 
effects on the active repression of ER by RIP140 (156). Moreover, RIP140 has been reported 
to interact with CtBP and disruption of this interaction leads to loss in RIP140- mediated 
repression of transcription (157). However, whether CtBP is involved in RIP140-mediated 
repression of SF-1 remains to be investigated. 
Our study suggests that the ability of RIP140 to repress SF-1 depends on several factors 
including promoter contexts, cell types and the expression levels of other coregulator proteins. 
Different TR-target genes have been demonstrated to recruit different p160/SRCs, each with 
different temporal recruitment patterns (125). It is likely that SF-1 also requires different sets 
of coactivators and corepressors to regulate its different target genes. Still, verification of this 
theory, which may contribute to the understanding of RIP140 function in regulation of 
different SF-1 target genes in different cells, is needed. We have observed that both RIP140 
and TIF2 are expressed at a higher level in Y1 cells than in COS-1 cells. The expression 
levels of coregulator proteins in different cells may influence the repressive function of 
overexpressed RIP140. Furthermore, since posttranslational modifications such as 
phosphorylation and acetylation have been reported to modulate RIP140 activity (157,202-
204), it would be of interest to examine the posttranslational status of RIP140 in different cell 
types subjected to stimulation of different signaling pathways. 
 
1.2. Regulation of SF-1 through interactions with p/CIP and TIF2 
SRC-1 has been reported to interact with and potentiate the transcriptional activity of SF-1 
through the proximal activation domain (pAF) and AF-2 domain (15). It has also been shown 
that TIF2/GRIP1 interacts with SF-1 and enhances the transcriptional activation of SF-1 target 
genes ((51), Paper II). We have demonstrated that p/CIP interacts with and acts as coactivator 
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for SF-1, and that the nuclear receptor interacting domain of p/CIP with its three LXXLL 
motifs is required for the SF-1 interaction. This finding has added the nuclear receptor SF-1 as 
a new member to the list of p/CIP-coactivated NRs that includes ER, GR, PR, TR, RXR, and 
RAR (103,104,106,236,237). Our results also confirm that all three members of the 
p160/SRC family stimulate SF-1 activity. A functional redundancy has been observed for 
other NRs and is believed to act as a safety mechanism in regulation of NR-mediated actions 
in case one or two of the p160/SRC members are disrupted (107). However, the biological 
significance of the individual p160/SRCs for SF-1 function remains to be investigated. 
The activation function 2 (AF-2) of several NRs is required for their ligand-dependent 
activation and is the determinant for their interaction with different coregulators (3). Ligand 
binding leads to changes in the conformation of NRs that form an optimal AF-2 binding 
surface for coactivators. The AF-2 of SF-1 is required for its interaction with SRC-1 and TIF2 
((15,51), Paper II), as well with p/CIP (Paper II). p/CIP and TIF2 require different amino 
acids in the AF-2 domain for transcriptional coactivation of SF-1, reflecting different 
mechanisms of SF-1 binding by these coactivators (Paper II). While the Glutamic acid 454 
(Glu454), which is a highly conserved amino acid in the AF-2 domain of NRs (238), is 
important for p/CIP to stimulate SF-1 transactivity, this residue is dispensable for TIF2-
mediated coactivation of SF-1. Different requirements for the conserved Glu residue by other 
NRs in interaction with coregulators have also been reported (239-241). TR mutated in the 
conserved Glu shows normal binding affinity for its ligand and normal interaction with the 
corepressor N-CoR, but is not able to bind to SRC-1 (240). In addition, TIF2 is able to rescue 
the low ligand-dependent transactivity of a Glu-mutant of AR (241) and the loss of ligand-
dependent transcriptional activation by a similar TR Glu-mutant (239). It seems that receptor 
interactions with different coregulators, particularly the p160/SRCs, are differentially affected 
by mutation of the conserved Glu residue and the subsequent conformational changes of the 
receptor. This may represent a mechanism by which NRs interact preferentially and 
differentially with p160/SRCs (121-123,125), and supports the fact that preferential and 
differential interactions rely on the LBD structure and the coactivator NR boxes 
(91,92,121,125-132). 
 
2. Regulation of GRIP1 by the cAMP/PKA signaling pathway 
Activation of the cAMP/PKA pathway results in downregulation of GRIP1 through 
ubiquitination and proteasmomal degradation (Paper III). It has been reported that elevation of 
cAMP leads to phosphorylation and stimulation of SRC-1 (187). In addition, PKA induce 
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phosphorylation of SRC-3 and enhances the recruitment of CBP (191). Although our 
preliminary data do not indicate that GRIP1/TIF2 is phosphorylated directly by PKA (data not 
shown), a more detailed analysis of GRIP1/TIF2 phosphorylation sites should be performed 
after stimulation of the PKA pathway. Phosphorylation site prediction of the GRIP1 protein 
sequence reveals a number of potential phosphorylation sites for PKA, which scatter from 
GRIP1 N- to the C-terminal regions. Another possibility is that PKA acts through another 
signaling mechanism such as the MAPK pathway that phosphorylates GRIP1 at Ser-736 
(188,189).  It should also be noted that GRIP1 is regulated by other posttranslational 
modifications such as sumoylation (232). Interestingly, acetylation (228) and methylation of 
SRC-3 (231) have been reported to modulate the SRC-3 coactivator function. Thus, the 
function of GRIP1 and the effects by PKA may also be related to other modes of 
modification.  
Coactivators of the p160/SRC family are targets for ubiquitination and proteasomal 
degradation induced by different ubiquitin conjugating enzymes (220,221). Since coactivators 
have been shown to associate and disassociate on promoters of NR-target genes in a dynamic, 
orderly and cyclic manner during transcriptional activation by NRs (118,119,173), it is 
conceivable that they are subjected to degradation. This would allow coactivators to exchange 
on the promoter and facilitate the transcription process. In certain cellular contexts, selective 
regulation of specific coactivators by degradation via the ubiquitin-proteasome pathway such 
as observed for GRIP1 in our report (Paper III) may modulate the relative intracellular levels 
of coactivators, and therefore may also mediate the remodeling of coactivator networks 
associated with the NRs. 
The functional effects of PKA-mediated degradation of GRIP1 on specific NRs remain to 
be investigated. As several hormones activate PKA (177,178), we have proposed that PKA-
mediated degradation of GRIP1 may represent a mechanism by which PKA-activating 
hormones can regulate the transcriptional activity of specific NRs, such as GR which has been 
shown to interact preferentially with GRIP1 (128). The transcriptional activity of GR has been 
reported to be regulated by cross-talk between glucocorticoids and the cAMP signaling in 
different extents depending on the promoter context (242-244). In one case, activation of the 
cAMP signaling by 8-Br-cAMP was shown to antagonize both the hormone-induced and 
basal transcription of GR target genes through inhibiting the interaction of general 
transcription factors with the promoter (244). Whether activation of cAMP modulates 
recruitment of GRIP1 to GR target gene promoters is presently not known. Furthermore, since 
coactivators of the p160/SRC family seem to functionally compensate for each other 
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(108,136), selective degradation of GRIP1 by activated PKA could lead to competition 
between different NRs for interaction with the limited pool of SRC-1 or SRC-3. This may 
result in global changes of NR-induced gene transcription in the cell, allowing a complicated 
coordinated cellular response to specific cAMP/PKA signaling. 
Modulation of the subcellular localization of coactivators may affect their availability for 
interaction with NRs. GRIP1 has been found to be localized in the nuclear compartment in a 
heterogeneous distribution pattern from uniform in nucleoplasm to highly concentrated in 
subnuclear foci ((101,220,245,246) and Paper III). We have demonstrated that activation of 
PKA leads to changes in the intranuclear distribution of GRIP1 and to the formation of 
subnuclear foci that are associated with components of the 20S proteasome and the 
promyelocytic leukemia (PML) protein. PML is known to be distributed in speckles in the 
nucleus and is associated with proteasomal degradation of ubiquitinated proteins 
(220,247,248). Studies have demonstrated that GRIP1 colocalizes with several NRs in 
subnuclear foci (245,246,249). Interestingly, Black and colleagues (250) have observed that 
ligand-induced activation of AR alters GRIP1 distribution from subnuclear foci to a more 
uniform nucleoplasmic pattern and they have proposed that subnuclear foci represent 
recruitment sites where AR interacts with its coactivators including GRIP1 and CBP prior to 
transcription. After this engagement at the foci, the coactivator-AR complex then relocates to 
the promoters and enhances transcriptional activation of target genes (250). Colocalization of 
GRIP1 with other transcriptional coactivators including CBP and pCAF in subnuclear foci has 
also been observed (220,250,251). However, it remains to be shown whether PKA activation 
modulates colocalization of GRIP1 with these coactivators as well as with NRs. 
Protein modification with ubiquitin molecules for targeting to proteasomal degradation is 
highly selective and specific. The selectivity and specificity rely on recognition signals which 
can be inherent and/or modified from the target protein and is determined by E3 ubiquitin 
ligases alone or in combination with E2 ubiquitin conjugating enzymes (206). Protein 
phosphorylation, binding to another protein (ancillary protein) as well as specific sequence 
motifs inherent in the protein primary structure such as destruction boxes or PEST sequences 
are among the ubiquitination and degradation recognition signals which have been observed 
primarily on transcription factors involved in inflammation and immune responses (T cell 
receptors, nuclear factor kappa-B) and proteins of cell cycle regulation (cyclins) (206,212). 
Still, little is known about the molecular mechanisms by which NRs, coactivators and 
corepressors are targeted to ubiquitination and proteasomal degradation, although an 
increasing number of these proteins have been demonstrated to be targets for the degradation 
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pathway. Phosphorylation of AR by the phosphatidylinositol 3-kinase (PI3K)-Akt pathway 
has been reported to promote ubiquitination and degradation of the receptor through a 
proteasome-dependent pathway (252). Likewise, binding of the carboxyl terminus of Hsp70-
interacting protein (CHIP) to GR has been shown to induce its ubiquitination and proteasomal 
degradation (211). Analysis of mouse GRIP1 and human TIF2 protein sequences by others 
(220,221) and by us (Paper III) has revealed three potential PEST motifs which could be 
involved in PKA-mediated targeting of GRIP1 to ubiquitination and degradation. However, 
our results do not indicate that these motifs are required for PKA-induced degradation of 
GRIP1 (Paper III). This suggests that other inherent sequence motifs of GRIP1 may act as 
degradation signals. It is possible that ubiquitination and degradation is signaled upon a 
complex coordination of several events including phosphorylation and/or other 
posttranslational modifications as well as interaction with other proteins. A recent report has 
demonstrated that during ligand-dependent activation of RAR, SRC-3 is phosphorylated by 
MAPK that leads to an initial potentiation of RAR-dependent transcription, but subsequently 
to inhibition of the transcription by promoting SRC-3 degradation (237). In addition, the 
mechanism of target recognition by E2 and E3 enzymes appears to be relatively distinct 
between different target proteins. While ubiquitination and degradation of SRC-2/TIF2 are 
induced by UBC5, 7 and 8, SRC-3 and SRC-1 are ubiquitinated and degraded by UBC2, 3, 4 
and 5, and UBC2 respectively (221). It would therefore be interesting to investigate whether 
UBC5, 7 and 8 are involved in the PKA-mediated ubiquitination of GRIP1, at least whether 
activation of the cAMP/PKA modulates the activity of these enzymes. The E3 ubiquitin 
ligases MDM2 of the RING-finger protein family are required for phosphorylation-induced 
ubiquitination and degradation of AR by Akt kinase (252,253). However, which E3 ligase that 
is specific and/or required for the PKA-dependent ubiquitination and proteasomal degradation 
of GRIP1 is still unknown. 
 
3. Regulation of GRIP1 by CREB 
In Paper IV, we have demonstrated that CREB mediates degradation of GRIP1, and that 
CREB is required for the PKA-activated degradation of GRIP1. The mechanism by which 
CREB leads to degradation of GRIP1 and the exact relation to the cAMP/PKA signaling 
pathway is unclear. We have observed that CREB which is mutated at the PKA 
phosphorylation site (CREBS133A), as well as a CREB deletion mutant lacking the KID 
domain, also induce GRIP1 degradation. The results suggest that CREB may regulate GRIP1 
through other mechanisms than phosphorylation at Ser-133. It has been reported that the 
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cAMP/PKA signaling cross-talks with a variety of other signaling pathways including the 
MAPK pathway (183,254). Furthermore, it has been shown that GRIP1 is regulated by the 
ERK and p38 of the MAPK signaling pathway (188,189). One possibility is that PKA 
regulates GRIP1 by interacting with another signaling pathway to stimulate phosphorylation 
of CREB at other sites than Ser-133. As all the identified putative phosphorylation sites for 
protein kinases including ERK and p38 MAPK, protein kinase C and B, and the Ca2+- 
calmodulin dependent kinase are located in the KID domain of CREB (182), our results do 
not to support this hypothesis. CREB is subjected to several other posttranslational 
modifications such as acetylation, ubiquitination, sumoylation and glycosylation that regulate 
its transcriptional activity (255-257). Whether any of these modifications of CREB is induced 
upon PKA activation and is implicated in the PKA-mediated downregulation of GRIP1 
remains unknown. 
Protein-protein interaction may induce proteasomal degradation (211). Interaction 
networks associated with CREB and GRIP1 are obviously complicated and regulated 
depending on the intracellular environment and exposure to extracellular signals. It is well 
established that CREB recruits and interacts with CBP/p300 upon activation of PKA (258). 
The interaction with CBP may serve as an important bridge for the interaction between CREB 
and NRs, as observed in the case of AR whose transactivity is stimulated after PKA activation 
(259). Furthermore, it has been reported that CREB physically interacts with CARM1 in a 
cAMP-dependent manner in hepatocytes (260). Since GRIP1 can bind to multiple NRs and 
recruit both CBP/p300 and CARM1 to interaction (107), it is conceivable that CREB 
associates with GRIP1 under certain circumstances. In this study we have demonstrated that 
CREB interacts directly with GRIP1. Thus we propose that CREB is involved in the PKA-
stimulated proteasomal degradation of GRIP1 protein via its direct interaction. This may 
represent a novel mechanism by which CREB and the cAMP/PKA signaling pathway act to 
downregulate GRIP1.  
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CONCLUSIONS 
Nuclear receptor coregulators are proteins that play central roles in promoting gene 
expression by nuclear receptors. This thesis adds important new knowledge to the 
coregulators that regulate the nuclear receptor Steroidogenic factor 1 as well as a number of 
other nuclear receptors. Based on the results presented in this thesis the following conclusions 
were drawn.  
 
1. The nuclear receptor coregulator RIP140 interacts with SF-1 in an AF-2 dependent 
manner, and several domains of RIP140 are involved in the protein-protein interaction. 
The carboxyl-terminal region that contains 4 of its 9 LXXLL motifs shows the 
strongest interaction with SF-1. RIP140 acts as a potent corepressor of SF-1, and 
inhibits a number of SF-1 responsive promoter genes. Histone deacetylase activity 
may partially explain the RIP140-mediated repression of SF-1 and competition by 
coactivators (p160/SRCs) counteracts the RIP140-mediated inhibition of SF-1 
dependent transcription.  
2. The coactivators p/CIP and TIF2/GRIP1 interact directly with SF-1 through its AF-2 
domain. Both coactivators stimulate SF-1 dependent transcription. While activation of 
the cAMP/PKA signaling pathway potentiated p/CIP-mediated coactivation of SF-1, 
cAMP/PKA impaired the ability of TIF2/GRIP1 to stimulate SF-1 mediated 
transactivation of different reporter genes in COS-1 and adrenocortical Y1 cells. 
Activation of cAMP/PKA also inhibits the TIF2/GRIP1 coactivation of a number of 
other nuclear receptors. Our results demonstrate that extracellular signals that activate 
the cAMP/PKA pathway differentially regulate coactivators of the p160/SRC family.  
3. Activation of cAMP/PKA signaling pathway leads to ubiquitination and proteasomal 
degradation of GRIP1. cAMP/PKA also regulates the intracellular distribution of 
green fluorescent protein-GRIP1, and stimulates the recruitment of GRIP1 to 
subnuclear foci that are colocalized with proteasome components. 
4. Degradation of GRIP1 induced by PKA activation depends on the transcription factor 
CREB, but phosphorylation of CREB at Ser-133 by PKA is not required for the 
CREB-mediated degradation of GRIP1. A novel protein-protein interaction between 
GRIP1 and CREB is identified, which may represent an important part of the 
mechanisms underlying GRIP1 degradation. 
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FUTURE PERSPECTIVES 
Our results suggest that RIP140 negatively regulates SF-1 transactivity probably through 
competition with the p160/SRCs for SF-1 binding and through recruitment of HDACs. This 
can be subjected to further studies on the recruitment of HDACs or other corepressors such as 
CtBP during repression of specific SF-1-target genes. Furthermore, the fact that RIP140 
coregulator function varies depending on the promoter contexts and cell type raise an 
interesting question of whether RIP140 is differently regulated in these different cellular 
contexts. Of note, the RIP140 expression levels were shown to be different in COS-1 versus 
Y1 cells. A study of posttranslational modifications of RIP140 in different cell types and/or 
under different cellular signaling would be relevant to answer the question. 
TIF2 and p/CIP coactivator functions are differentially regulated upon activation of PKA 
signaling. To understand the molecular mechanism underlying this differential regulation, 
characterization of posttranslational modifications of TIF2 and p/CIP upon activation of PKA 
should be performed. Moreover, a recent ChIP-based investigation has showed slightly 
different patterns of TIF2 and p/CIP recruitment to SF-1 target gene upon ACTH activation 
(57). A similar ChIP-based study which includes both basal and PKA-activated condition 
would be of significance since this could verify in vivo the important roles of p160/SRC 
coactivators for NR basal transactivity via interaction and may also reveal how different TIF2 
and p/CIP are recruited to NRs when the cAMP/PKA signaling is activated. 
One of the main focuses of this study is regulation of coregulator proteins by signals 
acting through the cAMP/PKA signaling pathway. To elucidate the molecular mechanism 
underlying this regulation, several questions should be answered, such as which signals the 
cAMP/PKA induces to target GRIP1/TIF2 to ubiquitination and proteasomal degradation. 
Mapping of GRIP1 domains that are required for its PKA-mediated downregulation may 
reveal an inherent sequence motif that acts as recognition signal and site for ubiquitination. 
Furthermore, it would be interesting to perform proteomic characterization of possible 
posttranslational modifications of GRIP1 induced upon activation of PKA, and to identify 
possible components of the ubiquitin-proteasome degradation pathway that is associated with 
GRIP1. The identification of CREB as a phosphorylation-independent negative regulator of 
GRIP1, a required mediator of PKA-induced degradation of GRIP1, and an interaction partner 
of GRIP1 has shed light on how PKA might regulate GRIP1. Mapping of CREB domains that 
are required for the interaction between GRIP1 and CREB should be characterised. 
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Adipogenesis and hepatic gluconeogenesis are cellular processes that are regulated by 
cAMP signaling. Altered regulation of adipogenesis is associated with obesity whereas 
hepatic gluconeogenesis is related to increased fasting plasma glucose and type 2 diabetes 
(261,262). CREB has been shown to modulate expression and transcriptional activity of the 
key regulators of these processes, including the nuclear receptor PPAR and its coactivator 
PGC-1 (263,264). In addition, it has been demonstrated that transgenic mice deficient in 
CREB exhibit fasting hyperglycemia and have a fatty liver phenotype (264). Interestingly, 
ablation of SRC-2/GRIP1 also leads to significant downregulation of hepatic genes involved 
in energy metabolism (141). In other words, reduction in SRC-2/GRIP1 is associated with 
decreased energy storage and increased energy utilization. One might speculate whether 
GRIP1 and its regulation by the cAMP/PKA pathway and CREB could play roles in 
adipogenesis and hepatic gluconeogenesis. Characterisation of the mechanisms underlying 
CREB-mediated regulation of GRIP1 could provide important insights in the understanding of 
biological functions of GRIP1 in energy metabolisms and obesity. 
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